Novel prognostic tool could improve clinical decision making in leukemia

Written by Rachel Jenkins, Future Science Group

A new prognostic tool, termed IPS-E, designed by researchers from the Institute of Oncology Research (Bellinzona, Switzerland), predicts how long a patient diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting treatment for their cancer. Recently published in Blood, it is hoped the tool will become a point-of-care resource to improve clinical decision making. “While some patients display a milder disease never requiring therapy, others present active disease shortly after diagnosis and require intervention,” commented Davide Rossi (Institute of Oncology Research). “The IPS-E is a simple and a robust prognostic tool based on routine clinical and...

To view the full article, please register now for access

It's completely free